11 research outputs found
The anti-inflammatory potency of biologics targeting tumour necrosis factor-alpha, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study
Background Biologics targeting inflammatory mediators can achieve clinical
improvements in hidradenitis suppurativa (HS). However, their clinical efficacy
shows great interpatient variability in daily practice.
Objectives To investigate the anti-inflammatory potency of a selection of currently
available biologics and prednisolone for the treatment of HS in an ex vivo skin culture system using lesional HS biopsies.
Methods Lesional skin samples from 10 patients with HS and skin samples from
five healthy controls were cultured ex vivo and exposed to prednisolone or biologics targeting tumour necrosis factor (TNF)-a, interleukin (IL)-17A, IL-12/23p40
or CD20 (adalimumab, infliximab, secukinumab, ustekinumab and rituximab,
respectively). Real-time quantitative polymerase chain reaction and cytokine bead
arrays were used to measure the inhibitory effect of the biologics on cytokines
and antimicrobial peptides (AMPs).
Results The relative mRNA expression o
High prevalence of hidradenitis suppurativa in patients with perianal fistula
Abstract
Background Perianal fistula is an abnormal communication between the anal canal and perianal skin. Hidradenitis suppurativa
(HS) is a chronic, auto-inflammatory skin disease in the intertriginous body areas, presenting with recurring abscesses, inflammatory nodules, and sinus tracts. The aim of this study was to determine the prevalence of HS in patients with a perianal fistula.
Methods All patients with perianal fistula visiting a specialized proctology clinic between July and September 2017 were
included and asked a validated diagnostic question for HS. Subsequently, physical examination was performed to objectively
assess the diagnosis and relevant patient characteristics.
Results In 6.6% (8/122) of patients, HS was diagnosed outside the perianal region. Four of these patients were newly diagnosed.
The fistulas in HS patients were classified as a superficial fistula (three), a blind ending fistula (two), and a transsphincteric fistula
(two). One patient had more than one type of fistula.
Conclusion The prevalence of HS in patients with a perianal fistula is at least 6.6%. This is higher than the prevalence reported in
the general European population (1%) suggesting an association between perianal fistulas and HS. We stress the importance to
screen for HS in patients with perianal fistulas in order to start appropriate anti-inflammatory treatment to reduce symptoms and
disease progression
Nicotine Dependency and Readiness to Quit Smoking among Patients with Hidradenitis Suppurativa
Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project
Factors associated with disease-specific life impact in patients with hidradenitis suppurativa: results from the Global VOICE project
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
Background Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives To measure associations between treatment satisfaction and clinical and treatment-related characteristics among patients with HS. Methods Treatment satisfaction was evaluated utilizing data from a cross-sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients' self-reported overall satisfaction with their current treatments for HS, rated on a five-point scale from 'very dissatisfied' to 'very satisfied'. Results The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1 center dot 99 [95% confidence interval (CI) 1 center dot 62-2 center dot 44, P < 0 center dot 001] times the odds of being satisfied with current treatment than participants not primarily treated by a dermatologist. Treatment with biologics was associated with higher satisfaction [odds ratio (OR) 2 center dot 36, 95% CI 1 center dot 74-3 center dot 19, P < 0 center dot 001] relative to treatment with nonbiologic systemic medications. Factors associated with lower treatment satisfaction included smoking (OR 0 center dot 78, 95% CI 0 center dot 62-0 center dot 99; active vs. never), depression (OR 0 center dot 69, 95% CI 0 center dot 54-0 center dot 87), increasing number of comorbidities (OR 0 center dot 88 per comorbidity, 95% CI 0 center dot 81-0 center dot 96) and increasing flare frequency. Conclusions There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication. Factors that appear to lower treatment satisfaction include active smoking, depression, accumulation of comorbid conditions and increasing flare frequency. Awareness of these factors may support partnered decision making with the goal of improving treatment outcomes. What is already known about this topic? Nearly half of patients with hidradenitis suppurativa report dissatisfaction with their treatments. What does this study add? Satisfaction with treatment is increased by receiving care from a dermatologist and treatment with biologics. Satisfaction with treatment is decreased by tobacco smoking, accumulation of comorbid conditions including depression, and higher flare frequency. What are the clinical implications of this work? Awareness of the identified factors associated with poor treatment satisfaction may support partnered decision making and improve treatment outcomes
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project
Background: A needs assessment for patients with hidradenitis suppurativa (HS) will support advancements in multidisciplinary care, treatment, research, advocacy, and philanthropy. Objective: To evaluate unmet needs from the perspective of HS patients. Methods: Prospective multinational survey of patients between October 2017 and July 2018. Results: Before receiving a formal HS diagnosis, 63.7% (n = 827) of patients visited a physician ≥5 times. Mean delay in diagnosis was 10.2 ± 8.9 years. Patients experienced flare daily, weekly, or monthly in 23.0%, 29.8%, and 31.1%, respectively. Most (61.4% [n = 798]) rated recent HS-related pain as moderate or higher, and 4.5% described recent pain to be the worst possible. Access to dermatology was rated as difficult by 37.0% (n = 481). Patients reported visiting the emergency department and hospital ≥5 times for symptoms in 18.3% and 12.5%, respectively. An extreme impact on life was reported by 43.3% (n = 563), and 14.5% were disabled due to disease. Patients reported a high frequency of comorbidities, most commonly mood disorders. Patients were dissatisfied with medical or procedural treatments in 45.9% and 34.6%, respectively. Limitations: Data were self-reported. Patients with more severe disease may have been selected. Conclusion: HS patients have identified several critical unmet needs that will require stakeholder collaboration to meaningfully address